Spots Global Cancer Trial Database for Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer
Official Title: Tocotrienol and Bevacizumab in Metastatic Colorectal Cancer. A Randomized Phase II Marker Trial
Study ID: NCT04245865
Conditions
Study Description
Brief Summary: This double blind, randomized phase II trial will investigate whether the addition of tocotrienol will improve the effect and lower the toxicity of standard chemotherapy and bevacizumab. Half of the patients will receive tocotrienol and the other half placebo. Treatment is planned for a period of maximum six months and will be discontinued earlier in case of progression or unacceptable toxicity.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Department of Oncology, Vejle Hospital, Vejle, , Denmark
Contact Details
Name: Torben F Hansen, MD, PhD
Affiliation: Department of Oncology, Vejle Hospital - University Hospital of Southern Denmark
Role: STUDY_CHAIR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
